Literature DB >> 24299545

Risk factors associated with struvite urolithiasis in dogs evaluated at general care veterinary hospitals in the United States.

Chika C Okafor1, David L Pearl, Sandra L Lefebvre, Mansen Wang, Mingyin Yang, Shauna L Blois, Elizabeth M Lund, Cate E Dewey.   

Abstract

OBJECTIVE: To identify factors associated with development of struvite urolithiasis in dogs evaluated at general care veterinary hospitals in the United States.
DESIGN: Retrospective case-control study. ANIMALS: 508 dogs with a first-time diagnosis of struvite urolithiasis and 7,135 control dogs. PROCEDURES: Electronic medical records of all dogs evaluated at 787 general care veterinary hospitals in the United States between October 2007 and December 2010 were reviewed to identify dogs that developed struvite urolithiasis and 2 groups of control dogs with no history of urolithiasis. Information extracted included diet, age, sex, neuter status, breed size category, hospital location, and date of diagnosis. Urinalysis results, urolith composition, and other disease conditions were recorded if applicable. Potential risk factors were assessed with univariable and multivariable regression analysis.
RESULTS: Toy- or small-sized breeds had significantly greater odds of struvite urolithiasis, compared with medium- or large-sized breeds. Neutering significantly increased the odds of this outcome in females only; sexually intact females were more likely to develop struvite urolithiasis than were sexually intact males, but only up to 5 years of age. Urinary factors significantly associated with the outcome were basic (vs acidic) pH, presence of RBCs or WBCs, protein concentration > 30 mg/dL, and ketone concentration ≥ 5 mg/dL. CONCLUSIONS AND CLINICAL RELEVANCE: Evaluation of demographic characteristics and urinalysis results may be useful in the early identification of struvite urolithiasis in dogs. Periodic urinalysis in dogs is recommended because of the potential health impact of a late diagnosis of urolithiasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24299545     DOI: 10.2460/javma.243.12.1737

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  8 in total

1.  Analysis of canine urolith submissions to the Canadian Veterinary Urolith Centre, 1998-2014.

Authors:  Doreen M Houston; Heather E Weese; Nick P Vanstone; Andrew E P Moore; J Scott Weese
Journal:  Can Vet J       Date:  2017-01       Impact factor: 1.008

2.  Comparison of body condition score and urinalysis variables between dogs with and without calcium oxalate uroliths.

Authors:  Stephanie M Kennedy; Jody P Lulich; Michelle G Ritt; Eva Furrow
Journal:  J Am Vet Med Assoc       Date:  2016-12-01       Impact factor: 1.936

3.  Struvite urolithiasis with eosinophilic polypoid cystitis in a shih tzu dog.

Authors:  Meagan A Walker
Journal:  Can Vet J       Date:  2018-02       Impact factor: 1.008

4.  Obstructive struvite ureterolithiasis in 4-month-old intact male Bernese mountain dog.

Authors:  Jennifer Ho; Justin Lavallée
Journal:  Can Vet J       Date:  2022-05       Impact factor: 1.075

5.  Lipoprotein cholesterol and triglyceride concentrations associated with dog body condition score; effect of recommended fasting duration on sample concentrations in Japanese private clinics.

Authors:  Shiho Usui; Hidemi Yasuda; Yuzo Koketsu
Journal:  J Vet Med Sci       Date:  2015-04-10       Impact factor: 1.267

Review 6.  Desexing Dogs: A Review of the Current Literature.

Authors:  Silvan R Urfer; Matt Kaeberlein
Journal:  Animals (Basel)       Date:  2019-12-05       Impact factor: 2.752

Review 7.  Animal models of naturally occurring stone disease.

Authors:  Ashley Alford; Eva Furrow; Michael Borofsky; Jody Lulich
Journal:  Nat Rev Urol       Date:  2020-11-06       Impact factor: 16.430

8.  Epidemiologic evaluation of calcium oxalate urolithiasis in dogs in the United States: 2010-2015.

Authors:  Vachira Hunprasit; Pamela J Schreiner; Jeffrey B Bender; Jody P Lulich
Journal:  J Vet Intern Med       Date:  2019-08-30       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.